Skip to main content

Table 1 Parameter estimates used in the model

From: Cost effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in the decision

Parameters

Baseline estimate

Variation (SEM)

Distribution

Source

Level of evidence

Infection-related events:

   Probability of CR-BSI

Modeled in stepwise incrementsa

Beta

Database

1

   RR mortality (CR-BSI)

1.06

0.18

Log normal

[1]

2

   Extra days in the ICU

2.41

0.83

Log normal

[22]

2

   Extra days on hospital ward

7.54

1.81

Log normal

  

Effectiveness A-CVCs (RR):

   SPC

0.54

0.62

Log transformed normal

[21]

1 +

   CH/SSD (ext)

0.66

0.17

   

   CH/SSD (int/ext)

0.70

0.43

   

   MR

0.39

0.43

   

Baseline probabilities of mortality:

   ICU mortality

0.098

0.002

Beta

Dataset

2

   Hospital mortality

0.069

0.001

Beta

Dataset

2

   Annual mortality post discharge

Year 1

0.050

0.002

Beta

[24]

2

 

Years 2 to 3

0.027

0.002

   
 

Years 4 to 5

0.028

0.002

   
 

Years 6 to 10

0.037

0.003

   
 

Years 11 to 15

0.042

0.003

   

   Underlying annual mortality

45 to 64 years

0.004

-

NA

[25]

1

 

65 to 84 years

0.030

-

   
 

85 + years

0.140

-

   

Utilities:

   Utility ICU

0.66

0.27

Beta

[28]

3

   Utilities population norms

50 to 59 years

0.80

0.22

Beta

[27]

3

 

60 to 69 years

0.79

0.19

   
 

70 to 79 years

0.75

0.25

   
 

80 + years

0.66

0.29

   

Costs, 2006 AUD:

   ICU bed day

3,021

-

NA

[31]

4

   Hospital bed day

843

-

NA

[32]

3

   Diagnostics CR-BSI

101.70

-

NA

Database

1

   Treatment CR-BSI

591.30

-

NA

Database

1

   Additional cost per catheter

SPC

22.36

-

NA

Database

1

 

CH/SSD (ext)

11.64

-

   
 

CH/SSD (int/ext)

41.35

-

   
 

MR

59.36

-

   
  1. aAvailable on request from the authors.
  2. A-CVCs, antimicrobial central venous catheters; CH/SSD, chlorhexidine silver sulfadiazine; CR-BSI, catheter related bloodstream infection; ICU, intensive care unit; int/ext, internally and externally coated; MR, minocycline and rifampicin; RR, relative risk; SPC, silver, platinum and carbon.